Naltrexone And Buprenorphine Market To Reach $8.42 Billion By 2030

Naltrexone And Buprenorphine Market Growth & Trends

The global naltrexone and buprenorphine market size is expected to reach USD 8.42 billion by 2030, growing at a CAGR of 12.41% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing growth primarily due to the rising incidence of substance use disorders, increasing government efforts to address the crisis, and growing awareness of treatments for opioid use disorder. These factors are anticipated to substantially boost industry expansion during the forecast period, fostering advancements and improving accessibility to addiction care solutions. 

The World Drug Report 2023 highlights global trends in drug use disorders, emphasizing opioids as the primary cause of death from overdose and significant contributors to years lost due to disability and premature death. Opioid Use Disorder (OUD) affects millions worldwide, with disparities in treatment access exacerbated by the COVID-19 pandemic. Regional variations in primary drugs of abuse include opioids in Europe and Asia, cocaine in Latin America, and methamphetamine in East & Southeast Asia. Stigma and discrimination hinder treatment efforts, with less than 20% of those needing help receiving it. The report calls for international cooperation to address these complex health and societal challenges. 

Furthermore, increasing government initiatives to combat the OUD crisis through multifaceted approaches are growing. In February 2024, with the approval of the SAMHSA, USD 46.6 million in supplemental Community Mental Health Services Block Grant and Substance Use Prevention, Treatment, and Recovery Services Block Grant funds have been allocated to mental health and substance use services. In addition, USD 67.5 million from U.S. Department of Treasury funds has been directed to support these efforts in Wisconsin. 

Moreover, industry players are driving growth in the market through strategic initiatives, such as enhanced distribution networks, strategic partnerships with healthcare providers, and increased research and development investments. For instance, in July 2023, Titan Pharmaceuticals, Inc. and Fedson, Inc. signed an Asset Purchase Agreement, under which Titan would sell part of ProNeura assets, such as its portfolio of medications for drug addiction and other early development initiatives built on the ProNeura drug delivery technology. The company's addiction portfolio comprised implant programs for Nalmefene and Probuphine. In addition, in September 2023, Camurus AB introduced Brixadi, a weekly and monthly medication containing Brixadi, indicated to treat moderate-to-severe OUD. These efforts aim to expand treatment accessibility and efficacy, propelling advancement significantly. 

 Request a free sample copy or view report summary: Naltrexone And Buprenorphine Market Report

Naltrexone And Buprenorphine Market Report Highlights

• North America accounted for the largest revenue share of 39.39% in 2023, driven by robust healthcare infrastructure, high prevalence of substance use disorder, and proactive government initiatives supporting addiction treatment.

• Based on product, the buprenorphine segment dominated the market with a share of 70.02% in 2023 and is anticipated to witness the fastest growth at a CAGR over the forecast period. The segment growth can be attributed to the various strategies adopted by key players such as product launches, collaboration, M&A, regulatory approvals, clinical trials proving efficacy, & other factors that enhance treatment initiation rates.

• Based on route of administration, the oral administration segment held the majority share of 55.87% in 2023. However, in buprenorphine segment, the injectable administration segment held the majority share of 65.04% in 2023.

• Based on application, the OUD segment dominated the market with a share of 69.03% in 2023. Naltrexone is widely recognized for their efficacy in managing OUD, leading to its extensive adoption in treatment programs.

• Based on distribution channel, the hospital pharmacies segment dominated the global market with a share of 48.26% in 2023. Growth can be attributed to their key role in administering parenteral OUD treatments, such as buprenorphine, ensuring physician-supervised care, and facilitating access to essential medications.

Naltrexone And Buprenorphine Market Segmentation

Grand View Research has segmented the global naltrexone and buprenorphine market based on the product, route of administration, application, distribution channel, and region:

Naltrexone & Buprenorphine Product Outlook (Revenue, USD Million, 2018 - 2030)

• Naltrexone

• Buprenorphine

  • BELBUCA

  • Sublocade

  • Suboxone

  • Zubsolv

  • Others

Naltrexone & Buprenorphine Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Naltrexone

  • Oral Administration

  • Injectable Administration

  • Implantable Administration

• Buprenorphine

  • Oral Administration

  • Injectable Administration

  • Implantable Administration

Naltrexone & Buprenorphine Application Outlook (Revenue, USD Million, 2018 - 2030)

• Naltrexone

  • Opioid use disorder (OUD)

  • Alcohol use disorder (AUD)

• Buprenorphine

  • Opioid use disorder (OUD)

Naltrexone & Buprenorphine Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Others

Naltrexone & Buprenorphine Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • Spain

  • France

  • Italy

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Naltrexone And Buprenorphine Market

• Indivior PLC

• Collegium Pharmaceutical (BioDelivery Sciences International, Inc.)

• Alkermes, Inc.

• Orexo US, Inc. (a part of Orexo AB)

• Titan Pharmaceuticals, Inc.

• Omeros Corporation

• Camurus

• Sun Pharmaceutical Industries Ltd